Vertex Pharmaceuticals Inc / Ma: Form 10-K for the period ended Dec 31, 2016
Filed with the SEC on Feb 23, 2017 and accepted by EDGAR at Feb 23, 2017, 20:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-10-01 to 2016-12-31 | $458.7m | us-gaap:Revenues |
| Cost of revenue | 3 months2016-10-01 to 2016-12-31 | $59.6m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2016-10-01 to 2016-12-31 | $248.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2016-01-01 to 2016-12-31 | $1.05bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2016-10-01 to 2016-12-31 | $109.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2016-01-01 to 2016-12-31 | $432.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2016-10-01 to 2016-12-31 | $39.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2016-01-01 to 2016-12-31 | $9.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2016-10-01 to 2016-12-31 | −$7.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2016-01-01 to 2016-12-31 | $16.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-10-01 to 2016-12-31 | $32.9m | us-gaap:NetIncomeLoss |
| Net income | 12 months2016-01-01 to 2016-12-31 | −$112.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-10-01 to 2016-12-31 | $0.13 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2016-01-01 to 2016-12-31 | −$0.46 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-10-01 to 2016-12-31 | $0.13 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2016-01-01 to 2016-12-31 | −$0.46 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-10-01 to 2016-12-31 | 247,757,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2016-01-01 to 2016-12-31 | 244,685,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2016-01-01 to 2016-12-31 | $236.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2016-01-01 to 2016-12-31 | $56.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2016-12-31 | $1.18bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-12-31 | $1.83bn | us-gaap:AssetsCurrent |
| Total assets | At period end2016-12-31 | $2.90bn | us-gaap:Assets |
| Current liabilities | At period end2016-12-31 | $792.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-12-31 | $1.56bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-12-31 | $1.16bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-17-000017. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.